<p class="abstract"><strong>Background:</strong> Carcinoma of the buccal mucosa is the most common cancer of the oral cavity in India and involvement of commissure poses unique challenge in reconstruction after surgery. Aim was to analyse the demographics, presentations and various treatment options of early carcinoma buccal mucosa involving oral commissure.</p><p class="abstract"><strong>Methods:</strong> A retrospective review from clinical case records at our institution between 2014 and 2019 were analysed. All the cases recruited were analysed based on patient characteristics, clinical presentation, surgical and adjuvant therapy rendered. Statistical analysis was done using SPSS 20 software.  </p><p class="abstract"><strong>Results:</strong> A total of 40 patients of primary carcinoma buccal mucosa with T1 to T3 disease involving commissure were analysed. Median age of presentation was 51 years with male preponderance (24:16). 32 patients were offered surgery as the initial line of management and 8 received definitive radiotherapy. The estimated 5-year survival was around 30%. Two patients with clinically T2 disease were upstaged in the postoperative histopathology to T3 and T4a respectively one due to depth of invasion &gt;10 mm and the other owing to commissural skin involvement detected only in the final HPE.</p><p class="abstract"><strong>Conclusions:</strong> Early carcinoma of the buccal mucosa clinically extending from commissure poses unique challenges in choosing treatment modalities. In view of the location of the tumour it poses a small chance of upstaging of early disease in the final histopathology.</p>

No abstract

Introduction: Uterine sarcomas are rare neoplasms with poor prognosis comprising around 2-6% of uterine malignancies. They include leiomyosarcomas, endometrial stromal sarcomas, undifferentiated sarcomas, carcinosarcomas (previously existed, but it does not exist anymore) and few other rare variants. Leiomyosarcomas are the most common uterine sarcoma. The most common clinical presentation is postmenopausal vaginal bleeding while others include lower abdominal pain and white discharge per vaginum. This study analyzes the general patient characteristics and survival data of uterine sarcoma patients treated in our institute. Materials and methods:The patients treated for uterine sarcomas in our institute from 2004 to 2019 were identified and their case records analyzed. The patient's baseline characteristics, stage distribution, recurrence patterns, survival, outcomes of laparoscopic, and open approaches in treating uterine sarcomas are all analyzed. Results: Totally, 31 patients were treated during the time period out of which 6 patients were lost the follow-up. The mean age of patients at diagnosis was 46.5 years. The most common type in our center was endometrial stromal sarcoma. Eleven (35%) patients had recurrence. Those with recurrences were offered surgery when it was limited to pelvis. The adjuvant chemotherapy and radiation were given as indicated. Four patients had a history of tamoxifen intake. Eight patients (25%) had died during the follow-up which makes up to 72% of the recurred patients. The median disease-free survival was 45 months after a median follow-up of 90 months. Conclusion: Although uterine sarcomas have poor prognosis, our patients had better prognosis on comparison with literature. The stage of the disease and the pathological type are the important factors determining prognosis. Laparoscopy offers better postoperative outcomes and larger studies are needed to demonstrate their oncological safety.

No abstract

Introduction: Response to neoadjuvant chemotherapy (NACT) is predicted by clinical examination alone in locally advanced breast carcinoma. This study uses thermo mammogram (TMG) to assess the response. Aim and Objectives: The aim is to study TMG changes during NACT in breast cancer and predict response to NACT in locally advanced carcinoma and to compare clinical response with TMG response/changes in any form. Patients and Methods: All patients with locally advanced breast cancer who had treated with NACT were included in this study. Baseline TMG picture was taken using illumina360° (digital robotic rotational thermography device for 360 degree view of each breast) system before chemotherapy. TMG was repeated before next cycle. All patients were also assessed clinically during and after each cycle of chemotherapy. To assess the potential of TMG in predicting tissue response to chemotherapy, the precool, postcool, and the temperature difference between precool and postcool before every cycle were analyzed. Results: A total of 19 patients were analyzed. Eight patients had complete clinical response, six patients had partial response, and five patients had static disease. Median of precool, temperature difference between precool and postcool for patients between no response and complete response did not show statistically significant difference. However, the median of postcool spot temperature showed statistically significant difference. Median of postcool temperature difference for patients between partial response and complete response showed statistically significant difference. The median of postcool spot temperature for patients with no response and partial response did not show statistically significant difference. Precool temperature difference for all the visits showed no statistically significant difference. Conclusion: This preliminary study suggests that the TMG has potential for monitoring NACT response in breast cancer patients. Postcool temperature measurement is an early indicator of response to NACT.